Research programme: selective androgen receptor modulator - Pfizer

Drug Profile

Research programme: selective androgen receptor modulator - Pfizer

Alternative Names: CE-590; SARMs - Pfizer

Latest Information Update: 04 Aug 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Male osteoporosis

Most Recent Events

  • 04 Aug 2009 No development reported (preclinical) for Male osteoporosis in USA (PO)
  • 22 Jun 2005 Preclinical trials in Male osteoporosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top